Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients
Conclusions: ACEi/ARB therapy is associated with an increased risk of hyperkalemia in anuric hemodialysis patients. The proportion of patients with normal sK concentrations decreased from 82 to 29% and with mild hyperkalemia increased from 18 to 52%. Severe hyperkalemia necessitating the interruption of ACEi/ARB therapy developed in 19% of patients. This suggests great caution in the widest utilization of this class of drugs in HD patients.Am J Nephrol 2018;48:79 –86
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Dialysis | Hemodialysis | Neurology | Potassium | Sodium | Study | Universities & Medical Training | Urology & Nephrology